L. Sequist

发表

Integrating genomic features for non-invasive early lung cancer detection

Ash A. Alizadeh, Tej D. Azad, Natalie S. Lui, 2020, Nature.

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2011, Science Translational Medicine.

Isolation of rare circulating tumour cells in cancer patients by microchip technology

S. Digumarthy, R. Tompkins, D. Haber, 2007, Nature.

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip

K. Isselbacher, D. Haber, L. Sequist, 2010, Proceedings of the National Academy of Sciences.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Jeffrey W. Clark, A. Iafrate, P. Jänne, 2010, The New England journal of medicine.

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

A. Iafrate, M. Mino‐Kenudson, L. Sequist, 2012, Science Translational Medicine.

Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?

M. Kalra, Atul Padole, S. Digumarthy, 2019, Medicine.

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Luca Toschi, A. Iafrate, P. Jänne, 2010, Cancer cell.

Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

Paul Baas, Ignacio I. Wistuba, Robert Pirker, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Corrigendum: RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis

Jordan C. Ciciliano, B. Wittner, S. Ramaswamy, 2012, Nature.

J NEOPLASMS OF THE LUNG 51 BIOLOGY OF LUNG CANCER

W. Pao, P. Massion, L. Sequist, 2015 .

Lung cancer screening: Clinical practice guidelines in oncology

Ella A. Kazerooni, Pierre P. Massion, Matthew B. Schabath, 2012 .

Detection of mutations in EGFR in circulating lung-cancer cells.

Mehmet Toner, Alona Muzikansky, Daniel Irimia, 2008, The New England journal of medicine.

Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells

Mehmet Toner, Elena Brachtel, David N Louis, 2013, Science Translational Medicine.

Tunable Nanostructured Coating for the Capture and Selective Release of Viable Circulating Tumor Cells

Eugene J. Lim, Joseph M. Martel, A. Aranyosi, 2015, Advanced materials.

Protein degradation/chaperone system and histone deacetylase pathway.

L. Sequist, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines.

Matthew B Schabath, Pierre P Massion, Mary E Reid, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

First‐Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

L. Sequist, K. O'Byrne, T. Mok, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.

S. Digumarthy, L. Sequist, A. Shaw, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

L. Sequist, R. Ramlau, D. Gerber, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

Chun-Ming Tsai, Dan Massey, Nobuyuki Yamamoto, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

L. Sequist, E. Smit, E. Felip, 2012 .

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.

David C. Smith, L. Sequist, F. Hodi, 2014 .

Lung cancer screening.

Matthew B Schabath, Pierre P Massion, Mary E Reid, 2003, Journal of the National Comprehensive Cancer Network : JNCCN.

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

S. Digumarthy, A. Iafrate, C. Channick, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

M. Ladanyi, A. Iafrate, M. Kris, 2015, Cancer.

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

L. Sequist, Jessica J. Lin, Alissa J. Cooper, 2022, Nature Reviews Clinical Oncology.

Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.

K. Ramchandran, J. Neal, H. Wakelee, 2021, Clinical lung cancer.

Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.

Dana Statton Thompson, S. Lam, L. Sequist, 2020, Clinical lung cancer.

Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program

L. Sequist, G. Oxnard, M. Chau, 2018, Oncology and Therapy.

Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer.

L. Sequist, J. Engelman, B. Drapkin, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

M. Erlander, H. Wakelee, L. Sequist, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract B25: Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686.

P. Angenendt, H. Wakelee, L. Sequist, 2013 .

SNaPshot multigene assay to detect mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs).

A. Iafrate, M. Mino‐Kenudson, L. Sequist, 2010 .

O10.3Rociletinib: an oral, irreversible, highly selective small molecule inhibitor of mutant EGFR including T790M

J. Neal, H. Wakelee, L. Sequist, 2015 .

Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).

S. Digumarthy, L. Sequist, D. Jackman, 2012 .

Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer.

P. Jänne, Bruce E. Johnson, L. Sequist, 2012 .

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Geoffrey R. Oxnard, Ross A. Soo, Matthew Meyerson, 2013, Science Translational Medicine.

Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma.

L. Sequist, F. Fintelmann, B. Jahagirdar, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Structural, biochemical, and clinical characterization of Epidermal Growth Factor Receptor (EGFR) exon 20 insertion mutations in lung cancer (Science Translational Medicine (2014) 6, (225er1))

M. Meyerson, M. Hanna, L. Sequist, 2014 .

Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer

Mehmet Toner, Ronald G. Tompkins, Alessandra L. Moore, 2010, Science Translational Medicine.

Emre Ozkumur Sorting of Rare Circulating Tumor Cells Independent − Dependent and − Inertial Focusing for Tumor Antigen

Jordan C. Ciciliano, D. Louis, D. Haber, 2013 .

A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.

L. Sequist, G. MacBeath, Keunchil Park, 2014 .

The Shifting Landscape for Lung Cancer: Past, Present, and Future

L. Sequist, A. Spira, A. Vachani, 2017 .

Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes!

L. Sequist, T. Lynch, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).

G. Giaccone, M. Ladanyi, A. Iafrate, 2013 .

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).

H. Wakelee, L. Sequist, B. Solomon, 2014 .

Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

M. Meyerson, P. Jänne, Kwok-Kin Wong, 2006, Clinical Cancer Research.

Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.

G. Scagliotti, L. Sequist, S. Novello, 2012, Clinical lung cancer.

Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC

G. Scagliotti, L. Sequist, F. Shepherd, 2014 .

Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).

H. Wakelee, L. Sequist, S. Ou, 2015 .

Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer

L. Sequist, P. Fidias, J. Temel, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

M. Kris, V. Rusch, C. Azzoli, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

203 POSTER Neratinib (HKI-272), an irreversible pan-ErbB receptor tyrosine kinase inhibitor: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer

Kwok-Kin Wong, L. Sequist, T. Lynch, 2008 .

Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398.

M. Hidalgo, L. Sequist, F. Ringeisen, 2014 .

Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study

C. Azzoli, L. Sequist, A. Shaw, 2021, ESMO open.

Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors.

L. Sequist, N. Pennell, 2007, Biomarkers in medicine.

Abstract 4832: Isolation and molecular characterization of circulating melanoma cells

Ben S. Wittner, B. Wittner, S. Ramaswamy, 2014 .

Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors

L. Sequist, J. Schellens, P. LoRusso, 2014 .

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer

M. Kris, C. Azzoli, J. Shrager, 2021, JCO precision oncology.

Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.

L. Sequist, H. Willers, M. Khandekar, 2018, The oncologist.

Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond.

J. Neal, L. Sequist, 2013, Translational lung cancer research.

Phase I/II trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIB or stage IV non-small cell lung cancer stratified by EGFR mutation status

P. Jänne, L. Sequist, T. Lynch, 2007 .

First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M.

J. Neal, H. Wakelee, L. Sequist, 2013 .

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.

L. Sequist, Keunchil Park, Yi-long Wu, 2019, Lung cancer.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

L. Sequist, K. O'Byrne, T. Mok, 2015, The Lancet. Oncology.

Brief Report of Biweekly Pemetrexed and Gemcitabine in Elderly Patients with Non-small Cell Lung Cancer

L. Sequist, P. Fidias, R. Heist, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

D. Haber, L. Sequist, D. Bell, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.

L. Sequist, R. Herbst, S. Gettinger, 2018, European journal of cancer.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Alona Muzikansky, Thomas J Lynch, Bruce E Johnson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM

B. Bernstein, Y. Drier, L. Sequist, 2017, Clinical Cancer Research.

iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors

P. Jänne, L. Sequist, T. Lynch, 2007 .

Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review.

L. Sequist, B. Halmos, M. Welch, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.

A. Iafrate, L. Chirieac, J. Beheshti, 2007, The Journal of molecular diagnostics : JMD.

Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors

David C. Smith, L. Sequist, S. Gettinger, 2017 .

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.

L. Sequist, T. Lynch, 2008, Annual review of medicine.

Abstract 1136: Detection and characterization of circulating tumor cells in localized and metastatic prostate cancer patients using CTC-Chip microfluidic technology

R. Tompkins, D. Haber, L. Sequist, 2010 .

A Th1/IFNg Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

J. Goeman, H. V. Houwelingen, J. Kirkwood, 2020 .

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

David C. Smith, L. Sequist, F. Hodi, 2014 .

Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

M. Socinski, R. Govindan, Kwok-Kin Wong, 2007, Clinical Cancer Research.

Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib

G. Giaccone, P. Jänne, L. Sequist, 2008 .

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

Gregory J Riely, Bruce E Johnson, G. Giaccone, 2009, Clinical Cancer Research.

Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

L. Sequist, S. Gettinger, J. Wigginton, 2013 .

Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC)

L. Sequist, S. Gettinger, J. Wigginton, 2012 .

Abstract 1729: An exploratory biomarker analysis evaluating the effect of the c-MET inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2 study

L. Sequist, S. Rodig, J. Schiller, 2012 .

LBA49Updated results from KEYNOTE-021 cohort G: A randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC

L. Sequist, H. Borghaei, S. Jalal, 2017 .

Rapid Hydroxychloroquine Toxicity in Cancer Therapy

J. Neal, H. Wakelee, L. Sequist, 2015 .

Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.

M. Marmor, J. Neal, H. Wakelee, 2015, American journal of ophthalmology.

RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance

Sridhar Ramaswamy, Mehmet Toner, Ben S. Wittner, 2015, Science.

Circulating tumour cells—monitoring treatment response in prostate cancer

Richard J. Lee, L. Sequist, D. T. Miyamoto, 2014, Nature Reviews Clinical Oncology.

DIAGNOSIS LUNG Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

M. Socinski, L. Sequist, S. Gettinger, 2013 .

The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

C. Azzoli, P. Jänne, R. Govindan, 2012 .

Epidermal growth factor receptor tyrosine kinase inhibitors and depression.

L. Sequist, J. Temel, T. Lynch, 2009, Journal of Clinical Oncology.

Afatinib as First‐line Treatment of Older Patients With EGFR Mutation‐Positive Non‐Small‐Cell Lung Cancer: Subgroup Analyses of the LUX‐Lung 3, LUX‐Lung 6, and LUX‐Lung 7 Trials

L. Sequist, K. O'Byrne, Keunchil Park, 2018, Clinical lung cancer.

Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib.

M. Erlander, J. Neal, H. Wakelee, 2016 .

Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study.

L. Sequist, R. Herbst, S. Gettinger, 2015 .

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC).

L. Sequist, N. Senzer, S. Gettinger, 2010 .

Title: A Randomized, Controlled Trial of Integrated vs. Standard Palliative Care in Patients with Advanced NSCLC

E. Lamont, L. Sequist, L. Traeger, 2008 .

A Th1/IFN g Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non – Small Cell Lung Cancer A

J. Goeman, H. V. Houwelingen, J. Kirkwood, 2020 .

24‐Month Overall Survival from KEYNOTE‐021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First‐Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

L. Sequist, H. Borghaei, S. Jalal, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.

L. Sequist, H. Borghaei, A. Patnaik, 2015 .

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

L. Sequist, Jessica J. Lin, Alissa J. Cooper, 2022, Nature Reviews Clinical Oncology.

TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): phase IIb results of the TIME study

L. Sequist, J. Nemunaitis, E. Juhász, 2014, Journal of Immunotherapy for Cancer.

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

L. Sequist, D. Costa, R. Ramlau, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).

L. Sequist, S. Gettinger, J. Wigginton, 2012 .

L. Sequist, K. O'Byrne, T. Mok, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer

L. Sequist, C. Fuchs, A. Hezel, 2008 .

Brief Report: Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.

L. Sequist, H. Borghaei, S. Jalal, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors

M. Hidalgo, L. Sequist, R. Camidge, 2012 .

Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).

C. Azzoli, M. Mino‐Kenudson, D. Haber, 2018 .

Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles

Mehmet Toner, Vishal Thapar, Leonora Balaj, 2018, Nature Communications.

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC

M. Mino‐Kenudson, L. Sequist, R. Heist, 2022, JTO clinical and research reports.

Targeting EGFR Exon 20 Insertions in NSCLC: Recent Advances and Clinical Updates

L. Sequist, C. Meador, Z. Piotrowska, 2021 .

SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.

M. Kris, C. Azzoli, P. Jänne, 2014 .

LTK fusions: A new target emerges in non-small cell lung cancer.

L. Sequist, T. Johnson, Jessica J. Lin, 2022, Cancer cell.

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Lauren L. Ritterhouse, G. Getz, S. Digumarthy, 2016 .

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

S. Digumarthy, L. Sequist, J. Engelman, 2016, JAMA oncology.

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Lauren L. Ritterhouse, G. Getz, S. Digumarthy, 2016, Cancer discovery.

Thoracic radiation therapy in locally advanced NSCLC patients (pts) with EGFR mutations.

R. Mak, L. Sequist, N. Choi, 2010 .

Expression of β-globin by cancer cells promotes cell survival during blood-borne dissemination

Sridhar Ramaswamy, Mehmet Toner, Min Yu, 2017, Nature Communications.

Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease

L. Sequist, L. Rolfe, A. Allen, 2015 .

Afatinib Therapy: Practical management of adverse events with an oral agent for non‐small cell lung cancer treatment

L. Sequist, M. Lacouture, D. O’Brien, 2018, Clinical journal of oncology nursing.

92PDFirst-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials

L. Sequist, L. Paz-Ares, M. Schuler, 2017 .

A bright future for KRAS inhibitors

L. Sequist, D. Bar-Sagi, E. Knelson, 2020, Nature Cancer.

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

L. Sequist, S. Ou, T. Mok, 2015, The Lancet. Oncology.

OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC

J. Lunceford, M. Ayers, L. Sequist, 2019, Journal of Thoracic Oncology.

Case records of the Massachusetts General Hospital. Case 17-2015. A 44-year-old woman with intractable pain due to metastatic lung cancer.

M. Mino‐Kenudson, L. Sequist, M. Kamdar, 2015, The New England journal of medicine.

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

G. Getz, A. Iafrate, L. Sequist, 2016, Nature Medicine.

Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

M. Meyerson, P. Jänne, D. Haber, 2006, Clinical Cancer Research.

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

Sridhar Ramaswamy, Mari Mino-Kenudson, Ryohei Katayama, 2014, Science.

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer

W. Guo, M. Socinski, Kwok-Kin Wong, 2013, Clinical Cancer Research.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Chun-Ming Tsai, Dan Massey, Nobuyuki Yamamoto, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.

M. Mino‐Kenudson, L. Sequist, J. Engelman, 2021, Cancer cell.

Lung cancer

L. Sequist, R. Heist, B. Solomon, 2021, The Lancet.

Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity

L. Sequist, J. Engelman, J. Settleman, 2019, Cell reports.

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Ash A. Alizadeh, Maximilian Diehn, Aaron M. Newman, 2016, Nature Communications.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

M. Mino‐Kenudson, J. Neal, H. Wakelee, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

M. Kris, J. Minna, I. Wistuba, 2017, Clinical Cancer Research.

Characteristics of Lung Cancers Harboring NRAS Mutations

M. Ladanyi, C. Rudin, M. Kris, 2013, Clinical Cancer Research.

Brain tumor cells in circulation are enriched for mesenchymal gene expression.

A. Iafrate, D. Louis, H. Wakimoto, 2014, Cancer discovery.

ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.

L. Sequist, S. Ramalingam, Z. Piotrowska, 2020 .

Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.

Sridhar Ramaswamy, Mehmet Toner, Ben S. Wittner, 2012, Cancer discovery.

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

David N Louis, Ultan McDermott, Jeffrey W. Clark, 2010, EMBO molecular medicine.

Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.

J. Neal, L. Sequist, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.

Manuel Hidalgo, Martin Schuler, Fabrice Andre, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

L. Sequist, M. Ahn, J. Yang, 2020, The Lancet. Oncology.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

J. Neal, H. Wakelee, L. Sequist, 2015, The New England journal of medicine.

Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer

P. Jänne, L. Sequist, D. Jackman, 2015, Cancer.

Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

Sridhar Ramaswamy, Mehmet Toner, Min Yu, 2013, Science.

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

S. Digumarthy, Y. Yagi, C. Azzoli, 2016, Clinical Cancer Research.

Stott with Localized and Metastatic Prostate Cancer Isolation and Characterization of Circulating Tumor Cells from Patients

Maria E. Kempner, A. Iafrate, R. Tompkins, 2010 .

Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy

Linda T. Nieman, B. Wittner, S. Ramaswamy, 2018, Proceedings of the National Academy of Sciences.

Scientific Advances in Thoracic Oncology 2016.

H. Groen, C. Rudin, R. Rami-Porta, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future.

L. Sequist, A. Spira, A. Vachani, 2017, American journal of respiratory and critical care medicine.

Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review.

L. Sequist, Z. Piotrowska, 2016, JAMA oncology.

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2018, Cancer discovery.

An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer.

A. Giobbie-Hurder, D. Haber, L. Sequist, 2018, Cancer discovery.

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

William Pao, Hongbin Ji, Nicolas Girard, 2011, European Respiratory Journal.

Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.

William C Hahn, David E Root, Matthew Meyerson, 2011, Cancer discovery.

amplification of C RKL ind uces t ra nsformation and epi dermal Growth Factor r ec eptor inh ibitor r es istance in hum an Non- s ma ll cel l lun g can cers

T. Golub, W. Hahn, M. Meyerson, 2011 .

am plification of CRKL in duces t r ansformation and ep idermal Growth Factor r e ceptor in hibitor r e sistance in hu man Non- s m all ce ll lu ng ca ncers

T. Golub, W. Hahn, M. Meyerson, 2011 .

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

G. Getz, K. Ross, S. Ramaswamy, 2015, Nature Communications.

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

L. Sequist, J. Engelman, Jeffrey A Engelman, 2015, The Lancet. Oncology.

Genetic Changes in Squamous Cell Lung Cancer: A Review

L. Sequist, J. Engelman, R. Heist, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

51 – Biology of Lung Cancer

W. Pao, P. Massion, L. Sequist, 2016 .

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Jeffrey W. Clark, L. Sequist, J. Engelman, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

C. Rudin, P. Hammerman, R. Govindan, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

William Pao, John D. Minna, Yu Shyr, 2014, JAMA.

EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.

L. Sequist, J. Engelman, T. Lynch, 2010, Neuro-oncology.

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Joshua M. Korn, J. Korn, P. Hammerman, 2019, Oncogene.

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

L. Sequist, K. O'Byrne, T. Mok, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

J. Shih, L. Sequist, S. Ou, 2012, The Lancet. Oncology.

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.

Susan Quinn, Revathi Ananthakrishnan, Thomas J Lynch, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RNA sequencing of pancreatic circulating tumour cells implicates WNT signaling in metastasis

Sridhar Ramaswamy, Mehmet Toner, Min Yu, 2012, Nature.

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

A. Drilon, B. Tuch, S. Dawson, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

David C. Smith, L. Sequist, S. Gettinger, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

Mehmet Toner, Martin Peifer, Mari Mino-Kenudson, 2018, Cancer discovery.

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care

L. Sequist, A. Dastur, J. Engelman, 2017, Cell reports.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Chia-Chi Lin, Tomonori Hirashima, Helen Mann, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acquired Resistance to First‐Line Afatinib and the Challenges of Prearranged Progression Biopsies

L. Sequist, J. Engelman, P. Fidias, 2016, Journal of Thoracic Oncology.

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

P. Jänne, D. Haber, L. Sequist, 2015, Clinical Cancer Research.

Acquired resistance to TKIs in solid tumours: learning from lung cancer

W. Pao, L. Sequist, D. Camidge, 2014, Nature Reviews Clinical Oncology.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

L. Sequist, H. Borghaei, S. Jalal, 2016, The Lancet. Oncology.

Epidermal Growth Factor Receptor–Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options

L. Sequist, Z. Piotrowska, 2015, Cancer journal.

Cancer Growth Factor Receptor ( EGFR ) Exon 20 Insertion Mutations in Lung Structural , Biochemical , and Clinical Characterization of Epidermal

M. Meyerson, M. Hanna, L. Sequist, 2013 .

Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations.

L. Sequist, T. Morán, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer.

Amita Sharma, M. Mino‐Kenudson, L. Sequist, 2011, The New England journal of medicine.

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

A. Iafrate, P. Jänne, L. Sequist, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted therapies: Optimal first-line therapy for NSCLC with EGFR mutations

J. Neal, L. Sequist, 2010, Nature Reviews Clinical Oncology.

First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.

J. Neal, L. Sequist, 2010, Clinical advances in hematology & oncology : H&O.

Testing for EGFR mutations: an emerging strategy for selecting treatment for adenocarcinoma of the lungs

L. Sequist, 2009 .

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

P. Jänne, D. Tenen, W. Pao, 2008, Clinical Cancer Research.

First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation: Positive Non-small Cell Lung Cancer Patients

L. Sequist, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Epidermal Growth Factor Receptor Mutation Testing in the Care of Lung Cancer Patients

M. Meyerson, Jeffrey C. Lee, D. Louis, 2006, Clinical Cancer Research.

Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.

L. Sequist, C. Langer, L. Horn, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

S. Digumarthy, A. Iafrate, L. Sequist, 2018, JCO precision oncology.

ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.

P. Jänne, I. Wistuba, L. Sequist, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation.

Brady J. McKee, H. Kauczor, D. Yankelevitz, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

International Association for the Study of Lung Cancer (IASLC)

G. Scagliotti, I. Wistuba, C. Swanton, 2019, Annals of Oncology.

Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.

R. Mak, L. Sequist, C. Benes, 2017, Cancer research.

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

G. Scagliotti, L. Sequist, F. Shepherd, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.

Markus Riester, Cyril H Benes, S. Digumarthy, 2018, JCO precision oncology.

The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients.

Mehmet Toner, Thomas J Lynch, Sunitha Nagrath, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A New Era of Protein-Based Assays for Cancer Early Detection.

L. Sequist, S. Skates, W. Haas, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patient-specific tumor growth trajectories determine persistent and resistant cancer cell populations during treatment with targeted therapies.

L. Sequist, H. Paganetti, Y. Maruvka, 2019, Cancer research.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

William Pao, Yumei Pan, Lu Wang, 2012, Proceedings of the National Academy of Sciences.

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

S. Digumarthy, M. Rivera, R. Jain, 2011, Cancer discovery.

Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.

Alona Muzikansky, Matthew Meyerson, Thomas J Lynch, 2007, The oncologist.

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

David C. Smith, J. Sosman, L. Sequist, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genotyping lung cancer is an investment in the future.

E. Lamont, C. Azzoli, L. Sequist, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

Edward S. Kim, Diane D. Liu, Jing Wang, 2017, Science Translational Medicine.

Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non–Small Cell Lung Cancer following Cisplatin Exposure: A Cell Culture Model of Second-line Erlotinib Treatment

D. Haber, L. Sequist, Sreenath V. Sharma, 2008, Clinical Cancer Research.

Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung.

L. Sequist, J. Settleman, J. Ackman, 2008, The New England journal of medicine.

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Ash A. Alizadeh, Aaron M. Newman, Kathleen A. Durkin, 2016, Nature Communications.

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial

P. Jänne, L. Sequist, J. Wolf, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

H. Wakelee, L. Sequist, S. Ou, 2014 .

A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non–Small-Cell Lung Cancer

S. Digumarthy, J. Neal, L. Sequist, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lung Cancer ScreeningPractice Guidelines in Oncology

D. Ettinger, A. Leung, E. Kazerooni, 2012 .

APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer

Christopher J. Ott, Jake June-Koo Lee, Chang S. Chan, 2021, bioRxiv.

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.

L. Sequist, Gregory Riely, E. Felip, 2020, The Lancet. Respiratory medicine.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2015, Cancer discovery.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

H. Wakelee, L. Sequist, D. Grimm, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab in Combination With Erlotinib or Gefitinib as First‐Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

L. Sequist, A. Patnaik, J. Yang, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer

M. Mino‐Kenudson, L. Sequist, A. Shaw, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

Marek Ancukiewicz, Thomas J Lynch, Rakesh K Jain, 2015, Proceedings of the National Academy of Sciences.

Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer.

M. Lawrence, S. Digumarthy, M. Mino‐Kenudson, 2019, Cancer discovery.

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

L. Sequist, S. Kobayashi, D. Costa, 2018, Clinical Cancer Research.

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically De fi ned Advanced Non – Small Cell Lung Cancer

M. Socinski, Kwok-Kin Wong, L. Sequist, 2013 .

Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR-Mutant and ALK-Positive Lung Cancers

L. Sequist, J. Engelman, 2015 .

A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer.

Ben S. Wittner, B. Wittner, A. Giobbie-Hurder, 2018, Cancer discovery.

Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells

Joseph M. Martel-Foley, D. Haber, L. Sequist, 2017, Scientific Reports.

Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer

L. Sequist, G. Zalcman, J. Cadranel, 2011, European Respiratory Journal.

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer

M. Lawrence, S. Digumarthy, A. Drilon, 2021, Clinical Cancer Research.

Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.

S. Digumarthy, L. Sequist, A. Shaw, 2019, Clinical lung cancer.

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.

L. Sequist, A. Shaw, H. Willers, 2016, The oncologist.

Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer.

L. Sequist, Z. Piotrowska, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Allelic Context of the C 797 S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity toSubsequent Treatment Strategies

Zo, L. Sequist, J. Engelman, 2015 .

Toward noninvasive genomic screening of lung cancer patients.

L. Sequist, J. Engelman, T. Lynch, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy

A. Niemierko, L. Sequist, H. Willers, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

L. Sequist, J. Engelman, Haichuan Hu, 2015, Clinical Cancer Research.

Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh

J. Neal, L. Sequist, 2010, Current treatment options in oncology.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Chao Huang, M. Socinski, J. Neal, 2018, Lung cancer.

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

L. Sequist, 2007, The oncologist.

Modeling Resistance and Recurrence Patterns of Combined Targeted–Chemoradiotherapy Predicts Benefit of Shorter Induction Period

L. Sequist, H. Paganetti, H. Willers, 2019, Cancer Research.

The Role of Phase III Trials in Modern Drug Development

L. Sequist, B. Chabner, Janet E. Murphy, 2014 .

Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.

A. Niemierko, L. Sequist, H. Shih, 2015, Neuro-oncology.

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Mari Mino-Kenudson, David C Christiani, A. Iafrate, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.

J. Gribben, D. Neuberg, L. Sequist, 2005, Blood.

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

L. Sequist, Keunchil Park, R. Doebele, 2019, The oncologist.

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.

L. Sequist, H. Borghaei, S. Jalal, 2019, Lung cancer.

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.

L. Sequist, H. Borghaei, A. Patnaik, 2018, Lung cancer.

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions

C. Azzoli, L. Sequist, A. Shaw, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.

S. Digumarthy, L. Sequist, D. Jackman, 2013, The oncologist.

Therapeutics , Targets , and Chemical Biology EGFR-Activating Mutations Correlate with a Fanconi Anemia – likeCellular Phenotype That Includes PARP Inhibitor Sensitivity

L. Sequist, Patricia Greninger, J. Settleman, 2013 .

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

L. Sequist, K. O'Byrne, T. Mok, 2016, British Journal of Cancer.

Phase Ib Study of High‐dose Intermittent Afatinib in Patients With Advanced Solid Tumors

P. Jänne, L. Sequist, R. Camidge, 2018, Clinical lung cancer.

Predictive Biomarkers and Personalized Medicine Characteristics of Lung Cancers Harboring NRAS Mutations

M. Ladanyi, C. Rudin, M. Kris, 2013 .

ROS1-targeted therapy in non-small cell lung cancer.

L. Sequist, 2012, Clinical advances in hematology & oncology : H&O.

Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer

L. Sequist, A. Wozniak, D. Harpole, 2009, Journal of Thoracic Oncology.

Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

J. Neal, L. Sequist, P. Fidias, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 2 Study of the HSP‐90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

H. Groen, L. Sequist, E. Smit, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)

L. Sequist, K. O'Byrne, T. Mok, 2017, The Patient - Patient-Centered Outcomes Research.

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

C. Paweletz, P. Angenendt, H. Wakelee, 2016, Clinical Cancer Research.

Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer

L. Sequist, N. Marcoux, 2019, Pulmonary Adenocarcinoma: Approaches to Treatment.

Long‐term safety and survival with gefitinib in select patients with advanced non–small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)

L. Sequist, F. Hirsch, P. Bunn, 2018, Cancer.

The Value of Early Depth of Response in Predicting Long‐Term Outcome in EGFR‐Mutant Lung Cancer

V. Gebski, I. Marschner, L. Sequist, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.

Y Huang, L. Sequist, K. O'Byrne, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.

R. Mak, J. Neal, L. Sequist, 2011, The oncologist.

Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.

S. Digumarthy, R. Mak, L. Sequist, 2011, The oncologist.

Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer

L. Sequist, L. Traeger, J. Temel, 2013, Palliative and Supportive Care.

Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer.

L. Sequist, L. Traeger, R. Heist, 2011, The oncologist.

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Sean P. Brown, C. Azzoli, D. Cahill, 2018, Cancer discovery.

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer

Julie M. Batten, S. Digumarthy, A. Iafrate, 2018, JCO precision oncology.

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.

S. Digumarthy, L. Sequist, H. Hatabu, 2016, Academic radiology.

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping

C. Azzoli, L. Sequist, A. Shaw, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies

D. Christiani, L. Sequist, P. Fidias, 2008, Cancer Epidemiology Biomarkers & Prevention.

Depression, inflammation, and epidermal growth factor receptor (EGFR) status in metastatic non-small cell lung cancer: A pilot study.

Naomi M Simon, Lara Traeger, N. Simon, 2017, Journal of psychosomatic research.

Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.

S. Digumarthy, L. Sequist, J. Lennerz, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review.

L. Sequist, Z. Piotrowska, A. Piper-Vallillo, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.

L. Sequist, Patricia Greninger, J. Settleman, 2013, Cancer research.

Detection of Impaired Homologous Recombination Repair in NSCLC Cells and Tissues

L. Sequist, C. Benes, J. Whetstine, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer.

M. Mino‐Kenudson, L. Sequist, S. Ou, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non – Small-Cell Lung Cancer : Results From the CA 209-003 Study

David C. Smith, Julie, L. Sequist, 2018 .

Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations.

L. Sequist, D. Ryan, J. Shepard, 2019, The oncologist.

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

P. Jänne, L. Sequist, T. Mitsudomi, 2018, Cancer.

A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer

J. Goeman, H. V. van Houwelingen, J. Kirkwood, 2019, Clinical Cancer Research.

1284P MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer

L. Sequist, L. Paz-Ares, D. Tan, 2020 .

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience

J. Neal, H. Wakelee, L. Sequist, 2022, JTO clinical and research reports.

246PA META-ANALYSIS OF BIOMARKERS IN THREE RANDOMIZED, PHASE 2 STUDIES OF MM-121, A LIGAND-BLOCKING ANTI-ERBB3 ANTIBODY, IN PATIENTS WITH OVARIAN, LUNG, AND BREAST CANCERS.

L. Sequist, G. MacBeath, J. Pearlberg, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel Agents in theTreatment of Lung Cancer : Advances in EGFR-Targeted Agents

Jeffrey C. Lee, D. Louis, R. Kucherlapati, 2006 .

An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients

D. Haber, L. Sequist, 2009 .

The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.

L. Sequist, D. Dias-Santagata, R. Heist, 2013, The Annals of thoracic surgery.

Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells

Joseph M. Martel-Foley, D. Haber, L. Sequist, 2017, Scientific Reports.

Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer.

S. Digumarthy, L. Sequist, A. Shaw, 2019, AJR. American journal of roentgenology.

An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma

D. Weitz, K. Isselbacher, D. Haber, 2017, Proceedings of the National Academy of Sciences.

Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer: Predicting Clinical Response to Kinase Inhibitors

D. Haber, L. Sequist, T. Lynch, 2005, Clinical Cancer Research.

A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer

L. Sequist, P. Fidias, R. Heist, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Biodegradable nano-films for capture and non-invasive release of circulating tumor cells.

Jason Z. Deng, D. Haber, L. Sequist, 2015, Biomaterials.

Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography

R. Barzilay, Adam Yala, L. Sequist, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib.

L. Sequist, J. Engelman, A. Shaw, 2016 .

Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells

D. Haber, L. Sequist, M. Toner, 2017, Nature Communications.

Microfluidic isolation of platelet-covered circulating tumor cells.

D. Haber, L. Sequist, Xi Luo, 2017, Lab on a chip.

Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).

H. Wakelee, L. Sequist, S. Ou, 2016 .

Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.

L. Sequist, Gregory Riely, E. Felip, 2016 .

OA 09.03 TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI

L. Sequist, M. Ahn, Chun-Ming Tsai, 2017 .

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON

Jie Yang, L. Sequist, M. Ahn, 2022, Cancer discovery.

Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.

L. Sequist, J. Engelman, A. Shaw, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EP08.02-140 MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib

L. Sequist, S. Novello, F. de Marinis, 2022, Journal of Thoracic Oncology.

MET amplification (amp) as a resistance mechanism to osimertinib.

C. Azzoli, L. Sequist, A. Shaw, 2017 .

Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.

L. Sequist, M. Edelman, M. Tan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.

J. Neal, H. Wakelee, L. Sequist, 2021, Clinical lung cancer.

Update to Rociletinib Data with the RECIST Confirmed Response Rate.

L. Sequist, J. Soria, D. Camidge, 2016, The New England journal of medicine.

ALK Resistance Mutations in ALK-Positive Lung Cancer

Lauren L. Ritterhouse, S. Digumarthy, A. Iafrate, 2016 .

First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.

L. Sequist, Gregory Riely, E. Felip, 2015 .

Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.

L. Sequist, H. Borghaei, A. Patnaik, 2016 .

FP14.03 Osimertinib + Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis

P. Jänne, L. Sequist, J.-Y. Han, 2021 .

Clinical Activity of Alectinib in Advanced RET‐Rearranged Non–Small Cell Lung Cancer

S. Digumarthy, P. Brastianos, L. Sequist, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice.

A. Iafrate, M. Mino‐Kenudson, L. Sequist, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor‐Mutant Lung Cancer

Fabian M. Troschel, Amita Sharma, S. Digumarthy, 2019, The oncologist.

Artificial Intelligence and Machine Learning in Lung Cancer Screening

R. Barzilay, L. Sequist, S. Adams, 2023, Thoracic Surgery Clinics.

Expanding the Reach and Grasp of Lung Cancer Screening.

L. Sequist, R. Osarogiagbon, P-C. Yang, 2023, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Incidence of Radiation Therapy Among Patients Enrolled in a Multidisciplinary Pulmonary Nodule and Lung Cancer Screening Clinic

L. Sequist, Y. Colson, H. Willers, 2022, JAMA network open.

The Role of Liquid Biopsies in Lung Cancer Screening.

L. Sequist, I. Dagogo-Jack, Z. Piotrowska, 2017, Seminars in roentgenology.

Phase II trial of oxaliplatin, pemetrexed, and bevacizumab in previously-treated advanced non-small cell lung cancer (NSCLC)

L. Sequist, R. Heist, J. Temel, 2007 .

Clinical and Imaging Features of Non-Small-Cell Lung Cancer in Young Patients.

S. Digumarthy, L. Sequist, D. Mendoza, 2020, Clinical lung cancer.

Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.

L. Sequist, E. Smit, Gregory Riely, 2022, European journal of cancer.

The anticipated next season of EGFR inhibitors.

L. Sequist, 2015, The Oncologist.

EGFR mutation status and survival after diagnosis of brain metastasis in non-small cell lung cancer.

L. Sequist, J. Engelman, K. Kahle, 2010 .

Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

Jie Yang, L. Sequist, B. Cho, 2019, Clinical Trials.

Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?

L. Sequist, Z. Piotrowska, 2015, The oncologist.

Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy.

S. Digumarthy, M. Mino‐Kenudson, L. Sequist, 2014 .

Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation‐positive non‐small cell lung cancer (NSCLC): Post‐hoc analyses of LUX‐Lung 3 (LL3) and LUX‐Lung 6 (LL6): 138PD

L. Sequist, K. O'Byrne, T. Mok, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).

H. Groen, L. Sequist, E. Smit, 2012 .

P3.01-039 Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm+) NSCLC: Analysis of Time on Treatment and OS

L. Sequist, K. O'Byrne, T. Mok, 2017 .

Transformation from NSCLC to SCLC: when did it happen? - Authors' reply.

L. Sequist, J. Engelman, Matthew G. Oser, 2015, The Lancet. Oncology.

Treatment of Advanced Non-Small Cell Lung Cancer in the Elderly

L. Sequist, P. Fidias, Lecia Sequist1, 2005, Seminars in respiratory and critical care medicine.

PS02.20 Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm+) NSCLC in LUX-Lung 3, 6 and 7: Topic: Medical Oncology

L. Sequist, Wenbo Tang, L. Paz-Ares, 2017 .

Single Cell RNA Profiling of Circulating Tumor Cells in Patients With Prostate Cancer

B. Wittner, S. Ramaswamy, T. Shioda, 2015 .

Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma.

L. Sequist, A. Farago, Z. Piotrowska, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy.

S. Digumarthy, C. Azzoli, M. Mino‐Kenudson, 2017, International journal of radiation oncology, biology, physics.

Targeting EGFR and ERBB3 in lung cancer patients: Clinical outcomes in a phase I trial of MM-121 in combination with erlotinib.

L. Sequist, D. Jackman, J. Pearlberg, 2012 .

Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

L. Sequist, S. Kobayashi, D. Costa, 2020, Clinical Cancer Research.

Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.

L. Sequist, J. Engelman, A. Shaw, 2015 .

Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates.

L. Sequist, C. Meador, Z. Piotrowska, 2021, Cancer discovery.

Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)

L. Sequist, A. Chiang, S. Gettinger, 2016 .

Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer

Atul Padole, S. Digumarthy, L. Sequist, 2019, Cancers.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.

H. Wakelee, L. Sequist, D. Grimm, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.

L. Sequist, L. Rolfe, A. Allen, 2015, The New England journal of medicine.

A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation.

C. Azzoli, P. Jänne, J. Neal, 2010 .

Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G

L. Sequist, H. Borghaei, S. Jalal, 2016 .

Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT?

M. Kalra, Atul Padole, S. Digumarthy, 2019, Cancer Imaging.

First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials

L. Sequist, K. O'Byrne, T. Mok, 2017 .

Abstract CT048: Phase 1/2 study of olaparib tablets and temozolomide in patients with small cell lung cancer (SCLC) following failure of prior chemotherapy

C. Azzoli, D. Haber, L. Sequist, 2017 .

Clinicopathologic and Longitudinal Imaging Features of Lung Cancer Associated with Cystic Airspaces: A Systematic Review and Meta-Analysis.

S. Digumarthy, M. Mino‐Kenudson, L. Sequist, 2020, AJR. American journal of roentgenology.

Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer

L. Sequist, U. Mahmood, N. Arvold, 2016, Technology in cancer research & treatment.

Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.

L. Sequist, H. Borghaei, S. Jalal, 2016 .

TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI

L. Sequist, M. Ahn, W. Su, 2019, Annals of Oncology.

Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer

T. Kolevska, L. Sequist, P. Fidias, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase 1b Study of Osimertinib Plus Savolitinib in Patients with EGFR Mutation-Positive, MET-Amplified, Non-Small Cell Lung Cancer after Progression on EGFR-Tyrosine Kinase Inhibitors

L. Sequist, M. Ahn, J. Yang, 2019, SSRN Electronic Journal.

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis

S. Digumarthy, L. Sequist, R. Heist, 2023, JTO clinical and research reports.

Non-small Cell Lung Cancer in Octogenarians: Treatment Practices and Preferences

L. Sequist, P. Fidias, A. Muzikansky, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lipodermatosclerosis secondary to pemetrexed use.

L. Sequist, P. Fidias, A. Shaw, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

M. Socinski, L. Sequist, S. Gettinger, 2013 .

A new BATTLE in the evolving war on cancer.

L. Sequist, J. Engelman, A. Muzikansky, 2011, Cancer discovery.

Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.

S. Digumarthy, R. Mak, L. Sequist, 2011, The oncologist.

OA 17.01 Pemetrexed-Carboplatin Plus Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update

L. Sequist, H. Borghaei, S. Jalal, 2017 .

First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.

L. Sequist, H. Borghaei, S. Jalal, 2017 .

B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma

M. Mino‐Kenudson, L. Sequist, I. Dagogo-Jack, 2023, JTO clinical and research reports.

OA 09.01 Characterizing the Genomic Landscape of EGFR C797S in Lung Cancer Using ctDNA Next-Generation Sequencing

L. Sequist, S. Gettinger, T. Owonikoko, 2017 .

Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).

L. Sequist, E. Smit, E. Felip, 2018 .

Therapy-induced APOBEC3A drives evolution of persistent cancer cells

Christopher J. Ott, Chang S. Chan, M. Lawrence, 2023, Nature.

Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC).

C. Azzoli, M. Mino‐Kenudson, L. Sequist, 2015 .

Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).

J. Barretina, L. Sequist, Gregory Riely, 2017 .

Abstract B136: Plasma EGFR mutation detection using a combined exosomal RNA and circulating tumor DNA approach in patients with acquired resistance to first-generation EGFR-TKIs

Tina Koestler, H. Wakelee, L. Sequist, 2015 .

Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.

S. Digumarthy, R. Mak, L. Sequist, 2011 .

COVID-19 Infection in a Lung Cancer Patient Population: Incidence, Presentation and Alternative Diagnostic Considerations

S. Digumarthy, L. Sequist, R. Heist, 2020, JTO Clinical and Research Reports.

Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations

S. Digumarthy, L. Sequist, R. Heist, 2020, JTO Clinical and Research Reports.

Abstract 5172: B cell content in the tumor microenvironment is associated with improved survival in stage II lung adenocarcinoma

M. Mino‐Kenudson, L. Sequist, M. Lanuti, 2022, Cancer Research.

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2

Erin L. Schenk, Nofisat Ismaila, L. Sequist, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status.

P. Jänne, L. Sequist, S. Gettinger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer

L. Sequist, R. Dziadziuszko, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear.

E. Campbell, L. Sequist, A. Bardia, 2019, The oncologist.

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

S. Digumarthy, M. Rivera, R. Jain, 2011, Cancer discovery.

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib

L. Sequist, A. Piper-Vallillo, 2019, JACC. CardioOncology.

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

L. Sequist, D. Costa, G. Oxnard, 2018, Clinical Cancer Research.

Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer.

A. Iafrate, M. Mino‐Kenudson, L. Sequist, 2017, JCO precision oncology.

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

S. Digumarthy, L. Sequist, J. Engelman, 2016, JAMA oncology.

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

L. Sequist, J. Engelman, Haichuan Hu, 2015, Clinical Cancer Research.

Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.

T. Golub, W. Hahn, M. Meyerson, 2011, Cancer discovery.

Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.

J. Neal, H. Wakelee, L. Sequist, 2019, Journal of Clinical Oncology.

EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.

M. Erlander, M. Socinski, J. Neal, 2018, JCO precision oncology.

The anticipated next season of EGFR inhibitors.

L. Sequist, 2015, The oncologist.

Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

L. Sequist, J. Yang, B. Cho, 2019, Clinical Trials.

Response to EGFR tyrosine kinase inhibitor (TKI) retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer (NSCLC) with acquired resistance.

L. Sequist, D. Jackman, M. Nishino, 2012 .

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

L. Sequist, H. Borghaei, S. Jalal, 2016, The Lancet. Oncology.

End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.

L. Sequist, R. Heist, J. Temel, 2016, Journal of palliative medicine.

L. Sequist, J. Yang, 2014 .

Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.

L. Sequist, A. Shaw, R. Heist, 2018 .

Isolation of circulating tumor cells using a microvortex-generating herringbone-chip

K. Isselbacher, D. Haber, L. Sequist, 2010, Proceedings of the National Academy of Sciences.

RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance

Ben S. Wittner, T. Shioda, D. Haber, 2015, Science.

Tunable Nanostructured Coating for the Capture and Selective Release of Viable Circulating Tumor Cells

Eugene J. Lim, Joseph M. Martel, A. Aranyosi, 2015, Advanced materials.

Update on Epidermal Growth Factor Receptor Inhibitor Development in Lung Cancer

L. Sequist, R. Dziadziuszko, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma

D. Weitz, K. Isselbacher, D. Haber, 2017, Proceedings of the National Academy of Sciences.

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

M. Erlander, H. Wakelee, L. Sequist, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway.

R. Mak, L. Sequist, C. Benes, 2017, Cancer research.

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC).

H. Wakelee, L. Sequist, M. Diehn, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer

L. Sequist, U. Mahmood, P. Heidari, 2016, Technology in cancer research & treatment.

A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies

D. Christiani, L. Sequist, P. Fidias, 2008, Cancer Epidemiology Biomarkers & Prevention.

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

Roman K. Thomas, M. Mino‐Kenudson, D. Haber, 2018, Cancer discovery.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Jeffrey W. Clark, L. Sequist, J. Engelman, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Jie Yang, L. Sequist, K. O'Byrne, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FP01.05 The ASCENT Trial: A Phase II Study of Neoadjuvant/Adjuvant Afatinib, Chemoradiation +/- Surgery for Stage III EGFR-Mutant NSCLC

P. Jänne, R. Mak, M. Mino‐Kenudson, 2021 .

Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer

G. Getz, M. Mino‐Kenudson, Risa Burr, 2023, medRxiv.

Role of sex in lung cancer risk prediction based on single low-dose chest computed tomography

L. Sequist, Ismail Tahir, Am. Fata, 2023, Scientific reports.

Acquired Resistance to Afatinib in EGFR-Mutant Lung Cancer

L. Sequist, A. Shaw, R. Heist, 2014 .

A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).

L. Sequist, J. Nieva, F. Shepherd, 2016 .

Lung Cancer in Women: The Past, Present, and Future.

L. Sequist, Nishwant Swami, Shruti Patel, 2023, Clinical lung cancer.

Early Detection and Interception of Lung Cancer.

L. Sequist, A. Potter, Allison E.B. Chang, 2024, Hematology/oncology clinics of North America.

Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3

Erin L. Schenk, Nofisat Ismaila, L. Sequist, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

L. Sequist, E. Felip, E. Garon, 2012 .

The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC

P. Jänne, L. Sequist, M. Lanuti, 2024, The Oncologist.

Abstract LB-144: Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy

Linda T. Nieman, Ben S. Wittner, A. Giobbie-Hurder, 2018, Clinical Research (Excluding Clinical Trials).

Incidence, characteristics, and survival of patients with EGFR-mutant lung cancers with EGFR T790M at diagnosis identified in the lung cancer mutation consortium (LCMC).

A. Iafrate, C. Rudin, M. Kris, 2013 .

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3

Erin L. Schenk, Nofisat Ismaila, L. Sequist, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.